Trial reportFertility and sterility2021
Lifestyle modifications alone or combined with hormonal contraceptives improve sexual dysfunction in women with polycystic ovary syndrome.
Trial report in Fertility and sterility, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00704912 (Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women), which is not on this map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Effect of oral contraceptive use on cardiorespiratory and immune function in premenopausal women involved in exercise: a systematic review and meta-analysis.Frontiers in physiology · 2026Pooled it
- Sexual function in women with polycystic ovary syndrome: a systematic review and meta-analysis.Human reproduction update · 2024Pooled it
- Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: A systematic review.Clinical endocrinology · 2023Pooled it
- Life Modifications and PCOS: Old Story But New Tales.Frontiers in endocrinology · 2022Pooled it
- The Hypothalamic Nuclei Implicated in the Regulation of Polycystic Ovary Syndrome: A Review of Its Clinical, Metabolic, and Endocrine Aspects.Molecules (Basel, Switzerland) · 2025Review
- POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Gestational anti-Müllerian hormone and testosterone excess combined with maternal adiposity program for polycystic ovary syndrome.Reproduction (Cambridge, England) · 2025Review
- Body shape concerns, sexual satisfaction, and associated factors among patients with polycystic ovarian syndrome: A cross-sectional study in Western Saudi Arabia.Saudi medical journal · 2025Article
- Total and bioavailable 25-hydroxyvitamin D is not associated with improved sexual dysfunction following vitamin D supplementation in women with polycystic ovarian syndrome: a pilot study.The journal of sexual medicine · 2024Article
- Sexual dysfunction in women with PCOS: a case control study.Human reproduction (Oxford, England) · 2023Observational
- Female sexual behavior is disrupted in a preclinical mouse model of PCOS via an attenuated hypothalamic nitric oxide pathway.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Impact of infertility duration on female sexual health.Reproductive biology and endocrinology : RB&E · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo describe the prevalence of female sexual dysfunction in a well-defined polycystic ovary syndrome (PCOS) population, and to assess the impact of common PCOS treatments on sexual function.
designSecondary analysis of a randomized controlled trial, oral contraceptive pills and weight loss in PCOS.
settingTwo academic medical centers. PATIENTS: Women with PCOS (N = 114) defined by the Rotterdam criteria.
interventionsContinuous oral contraceptive pill (OCP) or intensive lifestyle modification (Lifestyle) or the combination (Combined) for 16 weeks.
main outcome measuresChange in Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Revised (FSDS-R) scores after 16 weeks.
resultsThere was no change in total FSFI or FSDS-R score in any treatment group; however, an increase in the FSFI desire domain subscore was observed in the Lifestyle and Combined treatments, indicating improved sexual desire over the 16-week period. Overall, 33 participants (28.9%) met criteria for sexual dysfunction by FSFI criteria (baseline score ≤26.55). Among this group, FSFI score improved after 16 weeks of Lifestyle and Combined treatments. There was no change in prevalence of sexual dysfunction in treatment groups at 16 weeks. Use of OCPs did not alter FSFI scores. CONCLUSION(S): Female sexual dysfunction is highly prevalent among women with PCOS. Our findings suggest that common treatments for PCOS, including intensive lifestyle modification and the combination of intensive lifestyle modification and OCPs, have the potential to improve sexual function in these women; the mechanism for these improvements is likely multifactorial. CLINICAL TRIAL REGISTRATION NUMBER: NCT00704912.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.